Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vikas Mahavni

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Expert Opinion on Pharmacotherapy|June 27, 2002
Allopathic and complementary alternatives to hormone replacement therapyAmy C Eichholz, Vikas Mahavni, Anil K Sood
Cancer Gene Therapy|June 26, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller, Mark S Shahin, Jo Ann Horowitz, et al.
Cancer Gene Therapy|March 15, 2003
Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancerShu Fen Wen, Vikas Mahavni, Erlinda Quijano, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|June 27, 2002
Allopathic and complementary alternatives to hormone replacement therapyAmy C Eichholz, Vikas Mahavni, Anil K Sood
Cancer Gene Therapy|June 26, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller, Mark S Shahin, Jo Ann Horowitz, et al.
Cancer Gene Therapy|March 15, 2003
Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancerShu Fen Wen, Vikas Mahavni, Erlinda Quijano, et al.
Pageof 1